Kang Yang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Kang Yang has a total of 34 co-authors. Here are the top co-authors by number of shared publications:
Ting Liu
Department of Urology, Renmin Hospital of Wuhan University, Wuhan, China
8 shared publicationsYan Zeng
Department of Urology, Renmin Hospital of Wuhan University, Wuhan, China
7 shared publicationsHengcheng Zhu
Department of Urology, Renmin Hospital of Wuhan University, Wuhan, 443002, P.R. China
4 shared publicationsZhou Pan
Department of Urology, Renmin Hospital of Wuhan University, Wuhan, China
4 shared publicationsFei Xiao
Department of Urology, Renmin Hospital of Wuhan University, Wuhan, China
3 shared publications- Hengcheng Zhu
Department of Urology, Renmin Hospital of Wuhan University, Wuhan, P.R. China
3 shared publications
Latest Publications
- Open Access
- 13 March 2026
- Published by Springer Nature in Discover Oncology
- Vol. 17 (1)
A new cuproptosis-associated lncRNA signature predicts the prognosis of clear cell renal cell carcinoma patients
Objective Clear cell renal cell carcinoma (ccRCC) is the most common subtype of renal cell carcinoma. Cuproptosis is a new type of programmed cell death that is mediated by protein lipid acylation and is closely linked to mitochondrial metabolism. Methods The Cancer Genome Atlas (TCGA) database provided us with RNA-Seq data together with the related clinical and prognostic information. Using univariate Cox, 135 prognostic lncRNAs associated with cuproptosis were identified for use in prognostic model construction. Multivariate Cox analysis was subsequently used to further integrate these lncRNAs. We used subject operating characteristic (ROC) curve analysis and Kaplan-Meier (K-M) survival curve analysis to assess the model’s prognostic ability. In order to predict immune escape and potential therapeutic drugs in the two groups, we also looked at the differences in immunological and tumor mutational burden between the high- and low-risk groups. The quantitative polymerase chain reaction (Q-PCR) was then used to validate the risk model. Results The lncRNA profile linked to cuproptosis is used to divide patients into two risk categories, with the lower risk group having a better prognosis. The tumor mutational burden was larger, immune escape was more likely to occur, and immunotherapy results were generally worse in the high-risk group. The traditional chemotherapeutic medications sunitinib, AKT inhibitor VIII, rapamycin, and lapatinib were more effective in low-risk individuals. Six prognostic lncRNAs were ultimately confirmed in human cell lines, including HK-2, ACHN, 769-P, and CAKI-1. Conclusions A risk model based on six cuproptosis-related lncRNAs has a high predictive value for ccRCC and might be a medical target for cuproptosis.
- 13 March 2026
- Published by Springer Nature in Discover Oncology
- Vol. 17 (1)
Open AccessA new cuproptosis-associated lncRNA signature predicts the prognosis of clear cell renal cell carcinoma patients
Objective Clear cell renal cell carcinoma (ccRCC) is the most common subtype of renal cell carcinoma. Cuproptosis is a new type of programmed cell death that is mediated by protein lipid acylation and is closely linked to mitochondrial metabolism. Methods The Cancer Genome Atlas (TCGA) database provided us with RNA-Seq data together with the related clinical and prognostic information. Using univariate Cox, 135 prognostic lncRNAs associated with cuproptosis were identified for use in prognostic model construction. Multivariate Cox analysis was subsequently used to further integrate these lncRNAs. We used subject operating characteristic (ROC) curve analysis and Kaplan-Meier (K-M) survival curve analysis to assess the model’s prognostic ability. In order to predict immune escape and potential therapeutic drugs in the two groups, we also looked at the differences in immunological and tumor mutational burden between the high- and low-risk groups. The quantitative polymerase chain reaction (Q-PCR) was then used to validate the risk model. Results The lncRNA profile linked to cuproptosis is used to divide patients into two risk categories, with the lower risk group having a better prognosis. The tumor mutational burden was larger, immune escape was more likely to occur, and immunotherapy results were generally worse in the high-risk group. The traditional chemotherapeutic medications sunitinib, AKT inhibitor VIII, rapamycin, and lapatinib were more effective in low-risk individuals. Six prognostic lncRNAs were ultimately confirmed in human cell lines, including HK-2, ACHN, 769-P, and CAKI-1. Conclusions A risk model based on six cuproptosis-related lncRNAs has a high predictive value for ccRCC and might be a medical target for cuproptosis.
- Open Access
- 29 January 2026
- Published by Springer Nature in Communications Biology
- Vol. 9 (1)
LncRNA P4HA2-AS1 drives renal interstitial fibrosis via trim32-mediated k63 ubiquitination of ULK1 and autophagic dysregulation
Renal interstitial fibrosis (RIF), the central pathological driver of chronic kidney disease (CKD) progression, remains mechanistically incompletely defined. While long non-coding RNAs (lncRNAs) are emerging as critical regulators of CKD, their roles in RIF pathogenesis are poorly understood. Here, we identify the fibrosis-associated lncRNA P4HA2-AS1 as a key modulator of RIF through integrated analyses of unilateral ureteral obstruction (UUO) mice and TGF-β-stimulated human renal tubular epithelial cells (HK-2), combined with RNA sequencing, RNA pull-down, ubiquitination profiling, and autophagic flux assays. P4HA2-AS1 was markedly upregulated in fibrotic kidneys, and its suppression attenuated fibrotic phenotypes in vivo and in vitro while restoring autophagic flux. Mechanistically, P4HA2-AS1 directly binds the E3 ubiquitin ligase TRIM32, impeding its proteasomal degradation. This stabilization enhances TRIM32-mediated K63-linked ubiquitination of ULK1, a master autophagy initiator, leading to aberrant autophagic activation and fibrotic progression. Our study uncovers a previously unrecognized P4HA2-AS1/TRIM32/ULK1 axis that couples dysregulated autophagy to RIF, proposing lncRNA-protein interaction targeting as a therapeutic strategy against renal fibrosis.
- 29 January 2026
- Published by Springer Nature in Communications Biology
- Vol. 9 (1)
Open AccessLncRNA P4HA2-AS1 drives renal interstitial fibrosis via trim32-mediated k63 ubiquitination of ULK1 and autophagic dysregulation
Renal interstitial fibrosis (RIF), the central pathological driver of chronic kidney disease (CKD) progression, remains mechanistically incompletely defined. While long non-coding RNAs (lncRNAs) are emerging as critical regulators of CKD, their roles in RIF pathogenesis are poorly understood. Here, we identify the fibrosis-associated lncRNA P4HA2-AS1 as a key modulator of RIF through integrated analyses of unilateral ureteral obstruction (UUO) mice and TGF-β-stimulated human renal tubular epithelial cells (HK-2), combined with RNA sequencing, RNA pull-down, ubiquitination profiling, and autophagic flux assays. P4HA2-AS1 was markedly upregulated in fibrotic kidneys, and its suppression attenuated fibrotic phenotypes in vivo and in vitro while restoring autophagic flux. Mechanistically, P4HA2-AS1 directly binds the E3 ubiquitin ligase TRIM32, impeding its proteasomal degradation. This stabilization enhances TRIM32-mediated K63-linked ubiquitination of ULK1, a master autophagy initiator, leading to aberrant autophagic activation and fibrotic progression. Our study uncovers a previously unrecognized P4HA2-AS1/TRIM32/ULK1 axis that couples dysregulated autophagy to RIF, proposing lncRNA-protein interaction targeting as a therapeutic strategy against renal fibrosis.
- 31 December 2025
- Published by Elsevier in Materials Science and Engineering: C
- Vol. 182, 214697
Nanoplatform for renal ischemia-reperfusion injury repair: Modulating macrophage polarization, oxidative stress, and mitophagy
- 31 December 2025
- Published by Elsevier in Materials Science and Engineering: C
- Vol. 182, 214697
Nanoplatform for renal ischemia-reperfusion injury repair: Modulating macrophage polarization, oxidative stress, and mitophagy
- Open Access
- 23 July 2025
- Published by Bentham Science Publishers Ltd. in Current Cancer Drug Targets
- Vol. 25
SPON2 Suppresses Autophagy by Regulating the PI3K/AKT/mTOR Signaling Pathway in Renal Cell Carcinoma
Objective: SPON2 is an extracellular matrix constituent belonging to the Mindin-F-spondin protein family. Our previous study proved that SPON2 emerges as a novel biomarker in renal fibrogenesis. However, the role of SPON2 in regulation and its impact on RCC pro-gression remains uncertain. Methods: The TCGA and GEO databases were used to explore the expression of SPON2 in RCC. Western blot was used to detect the expression of SPON2 between RCC and normal samples. Survival analysis and gene set variation analysis were performed to discover the prognostic significance and underlying mechanism of SPON2 in RCC. The role of SPON2 was detected by CCK8, wound healing, invasion, and xenograft model assays. Autophagy-related experiments verified the bioinformatic findings. Results: Bioinformatic analysis revealed significantly higher SPON2 expression in RCC, which was found to be associated with improved overall survival in patients with high SPON2 levels. Detection of clinical samples revealed an increase in SPON2 expression within the context of ccRCC tissues. In addition, data from in vitro assays revealed that SPON2 overex-pression significantly enhanced the proliferative and migratory capacity of cell lines. Xeno-graft experiments demonstrated the accelerated tumor growth effect of SPON2. Mechanistic investigation showed that the PI3K/AKT/mTOR pathway was inhibited by SPON2. Conclusion: Our data illustrated that SPON2 functions as an oncogene in the tumorigenesis of RCC tumorigenesis, which is accompanied by an inverse relationship between SPON2 ex-pression levels and patient prognosis. The underlying mechanism likely involves the promo-tion of autophagy by modulating the PI3K/AKT/mTOR pathway.
- 23 July 2025
- Published by Bentham Science Publishers Ltd. in Current Cancer Drug Targets
- Vol. 25
Open AccessSPON2 Suppresses Autophagy by Regulating the PI3K/AKT/mTOR Signaling Pathway in Renal Cell Carcinoma
Objective: SPON2 is an extracellular matrix constituent belonging to the Mindin-F-spondin protein family. Our previous study proved that SPON2 emerges as a novel biomarker in renal fibrogenesis. However, the role of SPON2 in regulation and its impact on RCC pro-gression remains uncertain. Methods: The TCGA and GEO databases were used to explore the expression of SPON2 in RCC. Western blot was used to detect the expression of SPON2 between RCC and normal samples. Survival analysis and gene set variation analysis were performed to discover the prognostic significance and underlying mechanism of SPON2 in RCC. The role of SPON2 was detected by CCK8, wound healing, invasion, and xenograft model assays. Autophagy-related experiments verified the bioinformatic findings. Results: Bioinformatic analysis revealed significantly higher SPON2 expression in RCC, which was found to be associated with improved overall survival in patients with high SPON2 levels. Detection of clinical samples revealed an increase in SPON2 expression within the context of ccRCC tissues. In addition, data from in vitro assays revealed that SPON2 overex-pression significantly enhanced the proliferative and migratory capacity of cell lines. Xeno-graft experiments demonstrated the accelerated tumor growth effect of SPON2. Mechanistic investigation showed that the PI3K/AKT/mTOR pathway was inhibited by SPON2. Conclusion: Our data illustrated that SPON2 functions as an oncogene in the tumorigenesis of RCC tumorigenesis, which is accompanied by an inverse relationship between SPON2 ex-pression levels and patient prognosis. The underlying mechanism likely involves the promo-tion of autophagy by modulating the PI3K/AKT/mTOR pathway.
- 25 October 2024
- Published by Elsevier in Archives of Biochemistry and Biophysics
- Vol. 761, 110187
Oxalate-upregulated annexin A6 promotes the formation of calcium oxalate kidney stones by exacerbating calcium release-mediated oxidative stress injury in renal tubular epithelial cells and crystal-cell adhesion
- 25 October 2024
- Published by Elsevier in Archives of Biochemistry and Biophysics
- Vol. 761, 110187
Oxalate-upregulated annexin A6 promotes the formation of calcium oxalate kidney stones by exacerbating calcium release-mediated oxidative stress injury in renal tubular epithelial cells and crystal-cell adhesion
- Open Access
- 6 October 2023
- Published by Impact Journals, LLC in Aging
- Vol. 15 (19) , 10407-10427
PLCL1 suppresses tumour progression by regulating AMPK/mTOR-mediated autophagy in renal cell carcinoma
Autophagy has been increasingly recognized as a critical regulatory mechanism in the maintenance of cellular homeostasis. A previous study showed that phospholipase C-like protein 1 (PLCL1) is associated with lipid metabolism in renal cell carcinoma (RCC). However, it is unclear whether PLCL1 regulates autophagy, thereby influencing the progression of RCC. Bioinformatics analysis of five microarray datasets revealed that expression of PLCL1 is decreased in tumours and is positively correlated with prognosis in RCC patients. Three independent public datasets, clinical RCC tissues and RCC cell lines, were validated using real-time qPCR, western blotting and immunohistochemistry. Using wound healing and transwell assays, we observed that elevated PLCL1 levels decreased the migratory distance and the invasive number of 786-O and ACHN cells, but PLCL1 knockdown reversed these changes in 769P cell lines compared to those in controls. The results of flow cytometry analysis indicated that PLCL1 promotes apoptosis. Moreover, transcriptional analysis based on stable overexpression of PLCL1 in 786-O cells revealed that PLCL1 is related to autophagy, and western blotting and autophagic experimental results further verified these findings. Mechanistic investigations confirmed that PLCL1 activates the AMPK/mTOR pathway and interacts with decidual protein induced by progesterone (DEPP). Collectively, our data suggest that PLCL1 functions as a suppressor of RCC progression by activating the AMPK/mTOR pathway, interacting with DEPP, initiating autophagy and inducing apoptosis. PLCL1 may be a promising therapeutic target for the diagnosis and treatment of ccRCC patients.
- 6 October 2023
- Published by Impact Journals, LLC in Aging
- Vol. 15 (19) , 10407-10427
Open AccessPLCL1 suppresses tumour progression by regulating AMPK/mTOR-mediated autophagy in renal cell carcinoma
Autophagy has been increasingly recognized as a critical regulatory mechanism in the maintenance of cellular homeostasis. A previous study showed that phospholipase C-like protein 1 (PLCL1) is associated with lipid metabolism in renal cell carcinoma (RCC). However, it is unclear whether PLCL1 regulates autophagy, thereby influencing the progression of RCC. Bioinformatics analysis of five microarray datasets revealed that expression of PLCL1 is decreased in tumours and is positively correlated with prognosis in RCC patients. Three independent public datasets, clinical RCC tissues and RCC cell lines, were validated using real-time qPCR, western blotting and immunohistochemistry. Using wound healing and transwell assays, we observed that elevated PLCL1 levels decreased the migratory distance and the invasive number of 786-O and ACHN cells, but PLCL1 knockdown reversed these changes in 769P cell lines compared to those in controls. The results of flow cytometry analysis indicated that PLCL1 promotes apoptosis. Moreover, transcriptional analysis based on stable overexpression of PLCL1 in 786-O cells revealed that PLCL1 is related to autophagy, and western blotting and autophagic experimental results further verified these findings. Mechanistic investigations confirmed that PLCL1 activates the AMPK/mTOR pathway and interacts with decidual protein induced by progesterone (DEPP). Collectively, our data suggest that PLCL1 functions as a suppressor of RCC progression by activating the AMPK/mTOR pathway, interacting with DEPP, initiating autophagy and inducing apoptosis. PLCL1 may be a promising therapeutic target for the diagnosis and treatment of ccRCC patients.
- Open Access
- 26 September 2023
- Published by MDPI AG in Biomedicines
- Vol. 11 (10) , 2635
Basement Membrane-Associated lncRNA Risk Model Predicts Prognosis and Guides Clinical Treatment in Clear Cell Renal Cell Carcinoma
The basement membrane (BM) affects the invasion and growth of malignant tumors. The role and mechanism of BM-associated lncRNAs in clear cell renal cell carcinoma (ccRCC) are unknown. In this study, we identified biomarkers of ccRCC and developed a risk model to assess patient prognosis. We downloaded transcripts and clinical data from the Cancer Genome Atlas (TCGA). Differential analysis, co-expression analysis, Cox regression analysis, and lasso regression were used to identify BM-associated prognostic lncRNAs and create a risk prediction model. We evaluated and validated the accuracy of the model using multiple methods and constructed a nomogram to predict the prognosis of ccRCC. GO, KEGG, and immunity analyses were used to explore differences in biological function. We constructed a risk model containing six BM-associated lncRNAs (LINC02154, IGFL2-AS1, NFE4, AC112715.1, AC092535.5, and AC105105.3). The risk model has higher diagnostic efficiency compared to clinical characteristics and can be used to forecast patient prognoses. We used renal cancer cells and tissue microarrays to verify the expression of lncRNAs in the risk model. We found that knocking down LINC02154 and AC112715.1 could inhibit the invasion ability of renal cancer cells. The risk model based on BM-associated lncRNAs can well predict ccRCC and guide clinical treatment.
- 26 September 2023
- Published by MDPI AG in Biomedicines
- Vol. 11 (10) , 2635
Open AccessBasement Membrane-Associated lncRNA Risk Model Predicts Prognosis and Guides Clinical Treatment in Clear Cell Renal Cell Carcinoma
The basement membrane (BM) affects the invasion and growth of malignant tumors. The role and mechanism of BM-associated lncRNAs in clear cell renal cell carcinoma (ccRCC) are unknown. In this study, we identified biomarkers of ccRCC and developed a risk model to assess patient prognosis. We downloaded transcripts and clinical data from the Cancer Genome Atlas (TCGA). Differential analysis, co-expression analysis, Cox regression analysis, and lasso regression were used to identify BM-associated prognostic lncRNAs and create a risk prediction model. We evaluated and validated the accuracy of the model using multiple methods and constructed a nomogram to predict the prognosis of ccRCC. GO, KEGG, and immunity analyses were used to explore differences in biological function. We constructed a risk model containing six BM-associated lncRNAs (LINC02154, IGFL2-AS1, NFE4, AC112715.1, AC092535.5, and AC105105.3). The risk model has higher diagnostic efficiency compared to clinical characteristics and can be used to forecast patient prognoses. We used renal cancer cells and tissue microarrays to verify the expression of lncRNAs in the risk model. We found that knocking down LINC02154 and AC112715.1 could inhibit the invasion ability of renal cancer cells. The risk model based on BM-associated lncRNAs can well predict ccRCC and guide clinical treatment.
- Open Access
- 1 August 2023
- Published by AME Publishing Company in Translational Andrology and Urology
- Vol. 12 (8) , 1308-1320
Integrative analysis of deoxyribonuclease 1-like 3 as a potential biomarker in renal cell carcinoma
Background: Clear cell renal cell carcinoma (ccRCC), the most common subtype of renal cell carcinoma (RCC), is insensitive to radiotherapy and chemotherapy after surgery. Deoxyribonuclease 1-like 3 (DNASE1L3), an endonuclease that cleaves both membrane-encapsulated single- and double-stranded DNA, suppresses cell cycle progression, proliferation and metabolism in hepatocellular carcinoma cells. There is currently no established link between DNASE1L3 and RCC inhibition. We are gonging to explored the mechanism underlying the relationship between DNASEL1L3 and RCC. Methods: RNA sequencing data for RCC tissue and peritumoral tissue were downloaded from The Cancer Genome Atlas database and analyzed. The expression levels of DNASE1L3 in RCC and normal samples were verified using the Gene Expression Omnibus (GEO) database, Human Protein Atlas database and western blotting. The role and potential mechanism of DNASE1L3 were investigated by analysis of immune-related databases and wound healing, invasion, cell counting kit 8 and immunofluorescence assays. Results: We revealed that DNASE1L3 expression was downregulated in RCC group compared with control group [The Cancer Genome Atlas (TCGA): 7.98 vs. 10.87, Pvs. 0.322±0.027, Pvs. 832±67, PConclusions: This study strongly suggest that DNASE1L3 may be a promising potential biomarker for the diagnosis and treatment of ccRCC patients.
- 1 August 2023
- Published by AME Publishing Company in Translational Andrology and Urology
- Vol. 12 (8) , 1308-1320
Open AccessIntegrative analysis of deoxyribonuclease 1-like 3 as a potential biomarker in renal cell carcinoma
Background: Clear cell renal cell carcinoma (ccRCC), the most common subtype of renal cell carcinoma (RCC), is insensitive to radiotherapy and chemotherapy after surgery. Deoxyribonuclease 1-like 3 (DNASE1L3), an endonuclease that cleaves both membrane-encapsulated single- and double-stranded DNA, suppresses cell cycle progression, proliferation and metabolism in hepatocellular carcinoma cells. There is currently no established link between DNASE1L3 and RCC inhibition. We are gonging to explored the mechanism underlying the relationship between DNASEL1L3 and RCC. Methods: RNA sequencing data for RCC tissue and peritumoral tissue were downloaded from The Cancer Genome Atlas database and analyzed. The expression levels of DNASE1L3 in RCC and normal samples were verified using the Gene Expression Omnibus (GEO) database, Human Protein Atlas database and western blotting. The role and potential mechanism of DNASE1L3 were investigated by analysis of immune-related databases and wound healing, invasion, cell counting kit 8 and immunofluorescence assays. Results: We revealed that DNASE1L3 expression was downregulated in RCC group compared with control group [The Cancer Genome Atlas (TCGA): 7.98 vs. 10.87, Pvs. 0.322±0.027, Pvs. 832±67, PConclusions: This study strongly suggest that DNASE1L3 may be a promising potential biomarker for the diagnosis and treatment of ccRCC patients.
- Open Access
- 29 June 2023
- Published by Wiley in Journal of Cellular and Molecular Medicine
- Vol. 27 (16) , 2328-2339
GPD1L inhibits renal cell carcinoma progression by regulating PINK1/Parkin‐mediated mitophagy
Few approaches have been conducted in the treatment of renal cell carcinoma (RCC) after nephrectomy, resulting in a high mortality rate in urological tumours. Mitophagy is a mechanism of mitochondrial quality control that enables selective degradation of damaged and unnecessary mitochondria. Previous studies have found that glycerol‐3‐phosphate dehydrogenase 1‐like (GPD1L) is associated with the progression of tumours such as lung cancer, colorectal cancer and oropharyngeal cancer, but the potential mechanism in RCC is still unclear. In this study, microarrays from tumour databases were analysed. The expression of GPD1L was confirmed by RT–qPCR and western blotting. The effect and mechanism of GPD1L were explored using cell counting kit 8, wound healing, invasion, flow cytometry and mitophagy‐related experiments. The role of GPD1L was further confirmed in vivo. The results showed that GPD1L expression was downregulated and positively correlated with prognosis in RCC. Functional experiments revealed that GPD1L prevented proliferation, migration and invasion while promoting apoptosis and mitochondrial injury in vitro. The mechanistic results indicated that GPD1L interacted with PINK1, promoting PINK1/Parkin‐mediated mitophagy. However, inhibition of PINK1 reversed GPD1L‐mediated mitochondrial injury and mitophagy. Moreover, GPD1L prevented tumour growth and promoted mitophagy by activating the PINK1/Parkin pathway in vivo. Our study shows that GPD1L has a positive correlation with the prognosis of RCC. The potential mechanism involves interacting with PINK1 and regulating the PINK1/Parkin pathway. In conclusion, these results reveal that GPD1L can act as a biomarker and target for RCC diagnosis and therapy.
- 29 June 2023
- Published by Wiley in Journal of Cellular and Molecular Medicine
- Vol. 27 (16) , 2328-2339
Open AccessGPD1L inhibits renal cell carcinoma progression by regulating PINK1/Parkin‐mediated mitophagy
Few approaches have been conducted in the treatment of renal cell carcinoma (RCC) after nephrectomy, resulting in a high mortality rate in urological tumours. Mitophagy is a mechanism of mitochondrial quality control that enables selective degradation of damaged and unnecessary mitochondria. Previous studies have found that glycerol‐3‐phosphate dehydrogenase 1‐like (GPD1L) is associated with the progression of tumours such as lung cancer, colorectal cancer and oropharyngeal cancer, but the potential mechanism in RCC is still unclear. In this study, microarrays from tumour databases were analysed. The expression of GPD1L was confirmed by RT–qPCR and western blotting. The effect and mechanism of GPD1L were explored using cell counting kit 8, wound healing, invasion, flow cytometry and mitophagy‐related experiments. The role of GPD1L was further confirmed in vivo. The results showed that GPD1L expression was downregulated and positively correlated with prognosis in RCC. Functional experiments revealed that GPD1L prevented proliferation, migration and invasion while promoting apoptosis and mitochondrial injury in vitro. The mechanistic results indicated that GPD1L interacted with PINK1, promoting PINK1/Parkin‐mediated mitophagy. However, inhibition of PINK1 reversed GPD1L‐mediated mitochondrial injury and mitophagy. Moreover, GPD1L prevented tumour growth and promoted mitophagy by activating the PINK1/Parkin pathway in vivo. Our study shows that GPD1L has a positive correlation with the prognosis of RCC. The potential mechanism involves interacting with PINK1 and regulating the PINK1/Parkin pathway. In conclusion, these results reveal that GPD1L can act as a biomarker and target for RCC diagnosis and therapy.
- Open Access
- 12 April 2022
- Published by Springer Nature in Research Square
PLCL1 suppresses tumor progression by regulating AMPK/mTOR-mediated autophagy in renal cell carcinoma
Background: Autophagy has been increasingly recognized as a critical regulatory mechanism in the maintenance of cellular homeostasis. A previous study showed that phospholipase C-like protein 1 (PLCL1) is associated with the lipid metabolism of clear cell renal cell carcinoma (ccRCC). However, it is unclear whether PLCL1 regulates autophagy, thereby influencing the progression of ccRCC.Results: Bioinformatics analysis revealed and confirmed that expression of PLCL1 is decreased in tumors and is correlated with prognosis in ccRCC patients. Elevated PLCL1 levels decreased proliferation capacity and invasion while promoting apoptosis, but PLCL1 knockdown reversed these changes in ccRCC cells compared to controls. Mechanistic investigations confirmed that PLCL1 induces autophagy by activating the AMPK/mTOR pathway and interacting with DEPP. The results in mouse models demonstrated that PLCL1 inhibits ccRCC tumor growth.Conclusion: Our data suggest that PLCL1 suppresses ccRCC progression by activating the AMPK/mTOR pathway and interacting with DEPP, initiating autophagy and inducing apoptosis. PLCL1 may be a promising target for the treatment of ccRCC patients.
- 12 April 2022
- Published by Springer Nature in Research Square
Open AccessPLCL1 suppresses tumor progression by regulating AMPK/mTOR-mediated autophagy in renal cell carcinoma
Background: Autophagy has been increasingly recognized as a critical regulatory mechanism in the maintenance of cellular homeostasis. A previous study showed that phospholipase C-like protein 1 (PLCL1) is associated with the lipid metabolism of clear cell renal cell carcinoma (ccRCC). However, it is unclear whether PLCL1 regulates autophagy, thereby influencing the progression of ccRCC.Results: Bioinformatics analysis revealed and confirmed that expression of PLCL1 is decreased in tumors and is correlated with prognosis in ccRCC patients. Elevated PLCL1 levels decreased proliferation capacity and invasion while promoting apoptosis, but PLCL1 knockdown reversed these changes in ccRCC cells compared to controls. Mechanistic investigations confirmed that PLCL1 induces autophagy by activating the AMPK/mTOR pathway and interacting with DEPP. The results in mouse models demonstrated that PLCL1 inhibits ccRCC tumor growth.Conclusion: Our data suggest that PLCL1 suppresses ccRCC progression by activating the AMPK/mTOR pathway and interacting with DEPP, initiating autophagy and inducing apoptosis. PLCL1 may be a promising target for the treatment of ccRCC patients.